Literature DB >> 30713972

Neuroleptic-like Malignant Syndrome After Battery Depletion in a Patient with Deep Brain Stimulation for Secondary Parkinsonism.

Tamara Sauer1, Marc E Wolf1, Christian Blahak1, Hans-Holger Capelle2, Joachim K Krauss2.   

Abstract

Entities:  

Year:  2017        PMID： 30713972      PMCID： PMC6353417          DOI： 10.1002/mdc3.12496

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  9 in total

1.  Hardware failure in parkinsonian patients with chronic subthalamic nucleus stimulation is a medical emergency.

Authors:  M I Hariz; F Johansson
Journal:  Mov Disord       Date:  2001-01       Impact factor: 10.338

2.  Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.

Authors:  Gurutz Linazasoro; Nadege Van Blercom; Alfonso Castro; Maria Dolores Dapena
Journal:  Neurology       Date:  2004-08-10       Impact factor: 9.910

3.  Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinson's disease patient while actively treated with deep brain stimulation.

Authors:  Stewart A Factor
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

4.  Malignant deep brain stimulation-withdrawal syndrome in a patient with Parkinson's disease.

Authors:  Janina Neuneier; Michael T Barbe; Christian Dohmen; Mohammad Maarouf; Jochen Wirths; Gereon R Fink; Lars Timmermann
Journal:  Mov Disord       Date:  2013-07-15       Impact factor: 10.338

5.  Case report: recurrent parkinsonism-hyperpyrexia syndrome following discontinuation of subthalamic deep brain stimulation.

Authors:  Taro Kadowaki; Kenichi Hashimoto; Keisuke Suzuki; Yuka Watanabe; Koichi Hirata
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

6.  Uncoupling of dopaminergic and subthalamic stimulation: Life-threatening DBS withdrawal syndrome.

Authors:  Sigrid Reuter; Günther Deuschl; Daniela Falk; Maximilian Mehdorn; Karsten Witt
Journal:  Mov Disord       Date:  2015-07-17       Impact factor: 10.338

7.  Parkinsonism-hyperpyrexia syndrome after deep brain stimulation surgery: case report.

Authors:  Jong Hyun Kim; Taek-Hyun Kwon; Seong-Beom Koh; Jung Youl Park
Journal:  Neurosurgery       Date:  2010-05       Impact factor: 4.654

8.  A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.

Authors:  Hideki Takubo; Toshihide Harada; Takao Hashimoto; Yutaka Inaba; Ichiro Kanazawa; Sadako Kuno; Yoshikuni Mizuno; Eiji Mizuta; Miho Murata; Toshiharu Nagatsu; Shigenobu Nakamura; Nobuo Yanagisawa; Hirotaro Narabayashi
Journal:  Parkinsonism Relat Disord       Date:  2003-04       Impact factor: 4.891

Review 9.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210
  9 in total
  4 in total

Review 1.  Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.

Authors:  Jian-Yong Wang; Jie-Fan Huang; Shi-Guo Zhu; Shi-Shi Huang; Rong-Pei Liu; Bei-Lei Hu; Jian-Hong Zhu; Xiong Zhang
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  Rechargeable Pacemaker Technology in Deep Brain Stimulation: A Step Forward, But Not for Everyone.

Authors:  Joachim Runge; Johanna M Nagel; Christoph Schrader; Assel Saryyeva; Joachim K Krauss
Journal:  Mov Disord Clin Pract       Date:  2021-08-13

3.  Widening spectrum of neuroleptic malignant syndrome: Case series.

Authors:  Gunchan Paul; Sachi Singhal; Birinder S Paul; Gurparvesh Singh; Shriya Goyal
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2021-10-11

Review 4.  Technology of deep brain stimulation: current status and future directions.

Authors:  Joachim K Krauss; Nir Lipsman; Tipu Aziz; Alexandre Boutet; Peter Brown; Jin Woo Chang; Benjamin Davidson; Warren M Grill; Marwan I Hariz; Andreas Horn; Michael Schulder; Antonios Mammis; Peter A Tass; Jens Volkmann; Andres M Lozano
Journal:  Nat Rev Neurol       Date:  2020-11-26       Impact factor: 42.937
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.